Literature DB >> 36268255

How we use hepatic arterial infusion chemotherapy in the new era of systemic therapy?

Sadahisa Ogasawara1, Naoya Kanogawa1, Naoya Kato1.   

Abstract

Entities:  

Year:  2022        PMID： 36268255      PMCID： PMC9577980          DOI： 10.21037/hbsn-22-396

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   8.265


× No keyword cloud information.
  10 in total

1.  Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.

Authors:  MinKe He; QiJiong Li; RuHai Zou; JingXian Shen; WanQiang Fang; GuoSheng Tan; YuanMin Zhou; XiaoPing Wu; Li Xu; Wei Wei; Yong Le; ZhongGuo Zhou; Ming Zhao; Ying Guo; RongPing Guo; MinShan Chen; Ming Shi
Journal:  JAMA Oncol       Date:  2019-07-01       Impact factor: 31.777

2.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

Authors:  Josep M Llovet; Maria Isabel Real; Xavier Montaña; Ramon Planas; Susana Coll; John Aponte; Carmen Ayuso; Margarita Sala; Jordi Muchart; Ricard Solà; Joan Rodés; Jordi Bruix
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

3.  Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials.

Authors:  Keisuke Koroki; Sadahisa Ogasawara; Yoshihiko Ooka; Hiroaki Kanzaki; Kengo Kanayama; Susumu Maruta; Takahiro Maeda; Masayuki Yokoyama; Toru Wakamatsu; Masanori Inoue; Kazufumi Kobayashi; Soichiro Kiyono; Masato Nakamura; Naoya Kanogawa; Tomoko Saito; Takayuki Kondo; Eiichiro Suzuki; Shingo Nakamoto; Shin Yasui; Akinobu Tawada; Tetsuhiro Chiba; Makoto Arai; Tatsuo Kanda; Hitoshi Maruyama; Jun Kato; Satoshi Kuboki; Masayuki Ohtsuka; Masaru Miyazaki; Osamu Yokosuka; Naoya Kato
Journal:  Liver Cancer       Date:  2020-07-22       Impact factor: 11.740

4.  Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.

Authors:  Kazuomi Ueshima; Sadahisa Ogasawara; Masafumi Ikeda; Yutaka Yasui; Takeshi Terashima; Tatsuya Yamashita; Shuntaro Obi; Shinpei Sato; Hiroshi Aikata; Takumi Ohmura; Hidekatsu Kuroda; Takamasa Ohki; Kengo Nagashima; Yoshihiko Ooka; Masahiro Takita; Masayuki Kurosaki; Kazuaki Chayama; Shuichi Kaneko; Namiki Izumi; Naoya Kato; Masatoshi Kudo; Masao Omata
Journal:  Liver Cancer       Date:  2020-07-24       Impact factor: 11.740

5.  Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).

Authors:  Ning Lyu; Xun Wang; Ji-Bin Li; Jin-Fa Lai; Qi-Feng Chen; Shao-Long Li; Hai-Jing Deng; Meng He; Lu-Wen Mu; Ming Zhao
Journal:  J Clin Oncol       Date:  2021-12-14       Impact factor: 50.717

6.  Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.

Authors:  Qi-Jiong Li; Min-Ke He; Huan-Wei Chen; Wan-Qiang Fang; Yuan-Min Zhou; Li Xu; Wei Wei; Yao-Jun Zhang; Ying Guo; Rong-Ping Guo; Min-Shan Chen; Ming Shi
Journal:  J Clin Oncol       Date:  2021-10-14       Impact factor: 50.717

7.  Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice.

Authors:  Shaohua Li; Jie Mei; Qiaoxuan Wang; Feng Shi; Hongyan Liu; Ming Zhao; Lianghe Lu; Yihong Ling; Zhixing Guo; Yabing Guo; Xiaoming Chen; Ming Shi; Wan Yee Lau; Wei Wei; Rongping Guo
Journal:  Hepatobiliary Surg Nutr       Date:  2021-10       Impact factor: 8.265

8.  Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.

Authors:  Masatoshi Kudo; Kazuomi Ueshima; Osamu Yokosuka; Sadahisa Ogasawara; Shuntaro Obi; Namiki Izumi; Hiroshi Aikata; Hiroaki Nagano; Etsuro Hatano; Yutaka Sasaki; Keisuke Hino; Takashi Kumada; Kazuhide Yamamoto; Yasuharu Imai; Shouta Iwadou; Chikara Ogawa; Takuji Okusaka; Fumihiko Kanai; Kohei Akazawa; Ken-Ichi Yoshimura; Philip Johnson; Yasuaki Arai
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-04-07

9.  Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma.

Authors:  Hideki Iwamoto; Takashi Niizeki; Hiroaki Nagamatsu; Kazuomi Ueshima; Takako Nomura; Teiji Kuzuya; Kazuhiro Kasai; Yohei Kooka; Atsushi Hiraoka; Rie Sugimoto; Takehiro Yonezawa; Akio Ishihara; Akihiro Deguchi; Hirotaka Arai; Shigeo Shimose; Tomotake Shirono; Masahito Nakano; Shusuke Okamura; Yu Noda; Naoki Kamachi; Miwa Sakai; Hiroyuki Suzuki; Hajime Aino; Norito Matsukuma; Satoru Matsugaki; Kei Ogata; Yoichi Yano; Takato Ueno; Masahiko Kajiwara; Satoshi Itano; Kunitaka Fukuizumi; Hiroshi Kawano; Kazunori Noguchi; Masatoshi Tanaka; Taizo Yamaguchi; Ryoko Kuromatsu; Atsushi Kawaguchi; Hironori Koga; Takuji Torimura
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

10.  Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.

Authors:  Masatoshi Kudo; Kazuomi Ueshima; Stephan Chan; Tomohiro Minami; Hirokazu Chishina; Tomoko Aoki; Masahiro Takita; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Masahiro Morita; Chikara Ogawa; Yoshiyuki Wada; Masafumi Ikeda; Hiroshi Ishii; Namiki Izumi; Naoshi Nishida
Journal:  Cancers (Basel)       Date:  2019-07-31       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.